Related Experiment Videos

IGF-1 receptor inhibitors in clinical trials--early lessons

S John Weroha1, Paul Haluska

  • 1Department of Oncology, Mayo Clinic, 200 First St. SW., Rochester, MN 55905, USA.

Journal of Mammary Gland Biology and Neoplasia
|November 22, 2008
PubMed

Insights

Targeting the insulin-like growth factor (IGF) pathway, particularly the IGF-1 receptor, shows promise for overcoming resistance to breast cancer therapies. This review explores IGF-1 signaling

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The insulin-like growth factor (IGF) pathway is crucial for cancer cell growth, survival, and treatment resistance in various cancers, including breast cancer.
  • The IGF-1 receptor (IGF-1R) is a key component of the IGF system and a significant target for novel anti-cancer agents.
  • IGF-1 signaling contributes to resistance against standard breast cancer treatments like chemotherapy, hormonal therapy, and targeted therapies.

Purpose of the Study:

  • To review the scientific rationale for targeting the IGF-1 receptor and other components of the IGF-1 system in cancer therapy.
  • To examine the specific role of IGF-1 signaling in mediating resistance to established breast cancer treatments.
  • To summarize current and ongoing clinical trials investigating IGF-1 receptor inhibitors for breast cancer.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of the role of IGF-1 signaling in breast cancer therapy resistance.
  • Examination of clinical trial data for IGF-1 receptor inhibitors.

Main Results:

  • The IGF-1 pathway is implicated in resistance to chemotherapy, hormonal therapy, and erbB-targeted agents in breast cancer.
  • Several investigational agents targeting the IGF-1 receptor are in clinical and preclinical development.
  • Early clinical data on IGF-1 receptor inhibitors are being used to inform future treatment strategies.

Conclusions:

  • Targeting the IGF-1 receptor and related signaling pathways presents a viable strategy to overcome treatment resistance in breast cancer.
  • Understanding IGF-1's role in resistance is critical for designing effective combination therapies.
  • Further clinical investigation is warranted to optimize IGF-1 signaling inhibition strategies for breast cancer patients.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...